The Global HereditaryAngioedema Market, by Drug Class (C1 Esterase Inhibitor, KallikreinInhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route ofAdministration (Subcutaneous, Intravenous, and Oral), by Distribution Channel(Hospital Pharmacies, Retail Pharmacies, and e-Commerce) and by Region (NorthAmerica, Latin America, Europe, Asia Pacific, the Middle East, and Africa) wasvalued at US$ 1,563.7 million in 2016 and is projected to exhibit a CAGR of 9.1%over the forecast period (2017 – 2025).
The hereditary angioedema marketis expected to gain significant traction with the rising innovations for thedevelopment of novel drugs by the manufacturers and increasing R&Dinitiatives undertaken by research foundations.
Novel delivery platforms adoptedby manufacturers to drive the global market growth
Positive clinical trial resultsintegrated with assured safety profiles to cater the unmet need of the diseaseare the major factors to augment the global hereditary angioedema market in theforeseeable period. For instance, in 2016, RNAi-based candidate ARC-F12 byArrowhead Pharmaceuticals is currently in preclinical development and is apotential treatment for factor XII (F12) mediated diseases. The RNAi basedcandidate is expected to present opportunities in the treatment of hereditaryangioedema, thus the Arrowhead is currently conducting studies to advance thecandidate into the clinical trials. Furthermore, the novel gene therapy productcandidate by Adverum Biotechnologies named AADVM-053 is presently in thepreclinical trials for the treatment of patients HAE.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1292
ADVM-053 is an Adeno AssociatedVirus (AAV) based gene transfer vector that aims to provide persistent levelsof human C1-esterase inhibitor (C1-INH) to potentially correct the deficiencystate that can lead to life-threatening attacks.
Browse 58 Market Data Tables and32 Figures spread through 175 Pages and in-depth TOC on “Hereditary AngioedemaMarket”- Global Forecast to 2025.
The key players are adoptingstrategic collaborations and acquisitions for the development and expansion ofthe HAE portfolio and to accelerate respective pipelines for faster delivery ofthe products. For instance, In January 2018, BioCryst Pharmaceuticals and IderaPharmaceuticals merged to create a new rare-disease company. The companiescurrently have two phase 3 clinical compounds, including BioCryst’s BCX7353 andIdera’s IMO-8400. In 2017, Diplomat Pharmacy, Inc. acquired Focus Rx PharmacyServices Inc., to offer extensive solutions to meet the growing demand forinfusion therapies for individuals living with chronic conditions includinghereditary angioedema and other disorders. In 2015, Shire Plc acquired DyaxCorp. with a strategy to get access and achieve worldwide sales of leadpipeline product DX-2930, Phase 3-ready, fully-humanized monoclonal antibody.The FDA granted DX-2930 fast track, breakthrough therapy, and orphan drugdesignation in the EU.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/hereditary-angioedema-market-1292
Key Takeaways of the HereditaryAngioedema Market:
The global hereditary angioedemamarket is expected to exhibit a CAGR of 9.1% over the forecast period, owing tothe presence of high potential market and raising awareness of the condition inEurope, Asia Pacific, and Latin America
Among drug class, C1 esteraseinhibitor segment holds a dominant position in the hereditary angioedemamarket, owing to the robust number of drugs approved by the regulatory agencies
Some of the major playersoperating in the global hereditary angioedema market include CSL Behring, ShirePlc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., IonisPharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies andAttune Pharmaceuticals, Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1292
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
